Ben Tre Pharmaceutical JSC (STC:DBT) Return-on-Tangible-Asset: 0.00% (As of . 20)


STC:DBT Ben Tre Pharmaceutical JSC STC:DBT
13 GF Score
Price ₫12,700.00
! 1 Warning Sign
View Full Analysis

What is Ben Tre Pharmaceutical JSC Return-on-Tangible-Asset?

Ben Tre Pharmaceutical JSC STC:DBT 13 Return-on-Tangible-Asset is 0.00% as of . 20. GuruFocus rates STC:DBT with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 1,009 Drug Manufacturers companies, Ben Tre Pharmaceutical JSC ranks worse than 99107.93% on this metric.

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Ben Tre Pharmaceutical JSC's annualized Net Income for the quarter that ended in . 20 was ₫ Mil. Ben Tre Pharmaceutical JSC's average total tangible assets for the quarter that ended in . 20 was ₫ Mil. Therefore, Ben Tre Pharmaceutical JSC's annualized Return-on-Tangible-Asset for the quarter that ended in . 20 was 0.00%.

The historical rank and industry rank for Ben Tre Pharmaceutical JSC's Return-on-Tangible-Asset or its related term are showing as below:

STC:DBT's Return-on-Tangible-Asset is not ranked *
in the Drug Manufacturers industry.
Industry Median: 3.16
* Ranked among companies with meaningful Return-on-Tangible-Asset only.

Ben Tre Pharmaceutical JSC  (STC:DBT) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Ben Tre Pharmaceutical JSC Return-on-Tangible-Asset Related Terms


Ben Tre Pharmaceutical JSC Return-on-Tangible-Asset Historical Data

* Premium members only.

The historical data trend for Ben Tre Pharmaceutical JSC's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ben Tre Pharmaceutical JSC Return-on-Tangible-Asset Chart

Ben Tre Pharmaceutical JSC Annual Data
Trend
Return-on-Tangible-Asset

Ben Tre Pharmaceutical JSC Semi-Annual Data
Return-on-Tangible-Asset

STC:DBT vs ZTS, UTHR, VTRS: Return-on-Tangible-Asset Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ben Tre Pharmaceutical JSC's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ben Tre Pharmaceutical JSC Return-on-Tangible-Asset vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ben Tre Pharmaceutical JSC's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Ben Tre Pharmaceutical JSC's Return-on-Tangible-Asset falls into.


STC:DBT
13GF Score
Ben Tre Pharmaceutical JSC STC:DBT
Return-on-Tangible-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ben Tre Pharmaceutical JSC Return-on-Tangible-Asset Calculation

Ben Tre Pharmaceutical JSC's annualized Return-on-Tangible-Asset for the fiscal year that ended in . 20 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=/( (+)/ )
=/
= %

Ben Tre Pharmaceutical JSC's annualized Return-on-Tangible-Asset for the quarter that ended in . 20 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=/( (+)/ )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is one times the annual (. 20) net income data.

What does a Return-on-Tangible-Asset of 0.00% mean?
Ben Tre Pharmaceutical JSC (STC:DBT) has a Return-on-Tangible-Asset of 0.00% as of . 20. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Ben Tre Pharmaceutical JSC and its competitors. According to the industry distribution chart, Ben Tre Pharmaceutical JSC ranks #999999 out of 1009 companies in the Drug Manufacturers industry.
Is Ben Tre Pharmaceutical JSC's Return-on-Tangible-Asset too high?
Ben Tre Pharmaceutical JSC's current Return-on-Tangible-Asset is 0.00%. Based on the distribution chart, Ben Tre Pharmaceutical JSC ranks #999999 out of 1009 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ben Tre Pharmaceutical JSC has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Ben Tre Pharmaceutical JSC's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ben Tre Pharmaceutical JSC ranks #999999 out of 1009 companies for Return-on-Tangible-Asset. This places Ben Tre Pharmaceutical JSC in the lower half of its industry. The industry median Return-on-Tangible-Asset is 3.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.16, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Ben Tre Pharmaceutical JSC and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ben Tre Pharmaceutical JSC's current Return-on-Tangible-Asset is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ben Tre Pharmaceutical JSC stock overvalued right now?
Ben Tre Pharmaceutical JSC (STC:DBT) has a current Return-on-Tangible-Asset of 0.00%. The current Return-on-Tangible-Asset is 0.00%. Ben Tre Pharmaceutical JSC's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Ben Tre Pharmaceutical JSC (STC:DBT), the current Return-on-Tangible-Asset is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ben Tre Pharmaceutical JSC Business Description

Address No. 6A3, National Highway 60, Phu Tan Ward, Vinh Long Province, Ben Tre, VNM
Ben Tre Pharmaceutical JSC is based in Vietnam. The company is engaged in trading in pharmaceuticals, functional foods, vaccines, cosmetics, medical equipment, & medical machinery. It is also engaged in the Import and export of testing chemicals & biological products, Manufacturing medicines for human treatment, producing pharmaceuticals, chemicals, and medicinal herbs, and Leasing warehouses and premises.
13GF Score

Get the complete analysis for STC:DBT

Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫12,700.00
Price